Evaluation status available after sign-in
About the journal
Investigational New Drugs is a journal published by Springer Science+Business Media in Netherlands. It is listed in MEDLINE according to the sources read. Declared publication charge: 4,390 EUR. Facts are reproduced as recorded at their sources with their capture dates; PublishLens indicators are available after sign-in.
Basic facts
- Publisher
- Springer Science+Business Media
- ISSN
- 0167-6997 · 1573-0646
- Country
- Netherlands
- Access
- Not open access / not declared
- Declared publication charge
- 4,390 EUR
- Declared peer-review model
- peer_review
- Official website
- https://www.springer.com/journal/10637
Index listings
- MEDLINE · 1983-01-01
- Indexing
- MEDLINE
- APC
- 4,390 EUR
- Declared review time (DOAJ)
- —
- Actual review time (measured)
- 61 days received→accepted — computed from PubMed (n=97)
- Activity (OpenAlex)
- Active — latest works 2026
- PublishLens list status
- Shown after sign-in
- Counts for promotion at your university?
- Choose your university and rank below ↓
Methodology signals (dated facts from their sources)
Details of the evaluation under the published methodology are shown to signed-in users (free).
Create a free account to view the evaluationJournal profile
Descriptive metadata from public sources (DOAJ, OpenAlex, PubMed) as of the capture date shown — contains no assessment or judgment.
Works in OpenAlex
4007
Last recorded publication year
2026
Reported by OpenAlex in 1 of 3 sources (CC0 flags, not verified indexing)DOAJSciELOOpenAlex Core
h-index
115
i10-index
2511
From OpenAlex open data (CC0).
Editorial & policy6
- Observed digital preservation (Keepers registry)— snapshot 2026-10-05
- CLOCKSSPortico
- Editorial board
- Official page ↗
- Norwegian register (HK-dir)— 2026
- Level 1 — approved scholarly channel
- Open references deposited at Crossref
- 97%
- ORCID iDs in current deposits
- 24%
- Enrolled in Crossref Similarity Check
- ✓
- Deposits licence metadata at Crossref
- ✓
Identity & continuity2
- Source type
- journal
- NLM unique ID (PubMed)
- 8309330
Classification(no data)
No data available to the platform for this group
No platform data for: Classification — absence is not a judgment about the journal.
Subject areas
- Cancer therapeutics and mechanisms
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Cancer Treatment and Pharmacology
- Colorectal Cancer Treatments and Studies
- Cancer therapeutics and mechanisms
- Cancer therapeutics and mechanisms
- Lung Cancer Treatments and Mutations
Show all subjects (75)
- Lung Cancer Treatments and Mutations
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Colorectal Cancer Treatments and Studies
- Bioactive Compounds and Antitumor Agents
- Lung Cancer Research Studies
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Synthesis and biological activity
- Pharmacogenetics and Drug Metabolism
- Pancreatic and Hepatic Oncology Research
- Pancreatic and Hepatic Oncology Research
- HER2/EGFR in Cancer Research
- HER2/EGFR in Cancer Research
- Lung Cancer Diagnosis and Treatment
- Angiogenesis and VEGF in Cancer
- Pancreatic and Hepatic Oncology Research
- Cancer Immunotherapy and Biomarkers
- Cancer Immunotherapy and Biomarkers
- PI3K/AKT/mTOR signaling in cancer
- Drug Transport and Resistance Mechanisms
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Chronic Lymphocytic Leukemia Research
- Histone Deacetylase Inhibitors Research
- Histone Deacetylase Inhibitors Research
- Lung Cancer Research Studies
- Cancer-related Molecular Pathways
- Cancer-related Molecular Pathways
- Gastric Cancer Management and Outcomes
- Acute Myeloid Leukemia Research
- Prostate Cancer Treatment and Research
- PI3K/AKT/mTOR signaling in cancer
- Gastric Cancer Management and Outcomes
- Gastric Cancer Management and Outcomes
- Peptidase Inhibition and Analysis
- Peptidase Inhibition and Analysis
- Chemotherapy-induced cardiotoxicity and mitigation
- Chemotherapy-induced cardiotoxicity and mitigation
- Cancer, Hypoxia, and Metabolism
- Cancer, Hypoxia, and Metabolism
- Renal cell carcinoma treatment
- Breast Cancer Treatment Studies
- Head and Neck Cancer Studies
- Cell death mechanisms and regulation
- Microtubule and mitosis dynamics
- Melanoma and MAPK Pathways
- Glioma Diagnosis and Treatment
- Hepatocellular Carcinoma Treatment and Prognosis
- Angiogenesis and VEGF in Cancer
- Angiogenesis and VEGF in Cancer
- Renal cell carcinoma treatment
- Renal cell carcinoma treatment
- Multiple Myeloma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug Transport and Resistance Mechanisms
- Multiple Myeloma Research and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Drug Transport and Resistance Mechanisms
- Neuroendocrine Tumor Research Advances
- Microtubule and mitosis dynamics
- Neuroendocrine Tumor Research Advances
- Microtubule and mitosis dynamics
- Melanoma and MAPK Pathways
- Melanoma and MAPK Pathways
- Lymphoma Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Community confirmations — what users saw in MJL or Scopus Sources; not platform verification and never part of any score.
Loading community confirmations…
The journal's record in other sources:Web of Science MJLDOAJ